CLNN insider trading
Consumer DefensiveClene Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Company website: clene.com
CLNN insider activity at a glance
FilingIQ has scored 174 insider transactions for CLNN since May 24, 2021. The most recent filing in our index is dated May 12, 2026.
Across the full history, 44 open-market purchases
and 80 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CLNN insider trades is 53.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CLNN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Consumer Defensive tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CLNN?
- FilingIQ tracks 174 Form 4 insider transactions for CLNN (Clene Inc.), covering filings from May 24, 2021 onwards. 25 of those were filed in the last 90 days.
- Are CLNN insiders net buyers or net sellers?
- Across the full Form 4 history for CLNN, 44 transactions (25%) were open-market purchases and 80 (46%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CLNN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CLNN in?
- Clene Inc. (CLNN) is classified in the Consumer Defensive sector, specifically Packaged Foods, with a current market capitalisation of $47.94M.
Methodology & sources
Every CLNN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.